Status | Study |
NOT_YET_RECRUITING |
Study Name: Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. Condition: Chronic Myelomonocytic Leukemia Date: 2023-09-15 Interventions: CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule der |
RECRUITING |
Study Name: Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm Condition: Chronic Myelomonocytic Leukemia Date: 2022-10-27 Interventions: Undergo collection of blood and buccal samples |
Recruiting |
Study Name: A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) Condition: Leukemia, Myelomonocytic, Chronic Date: 2017-01-24 Interventions: Drug: Cohort 1, Ceplene® and Proleukin® |
Recruiting |
Study Name: Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Condition: Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome Date: 2016-10-13 Interventions: Drug: Atezolizumab Given IV |
Recruiting |
Study Name: Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Condition: Myelodysplastic Syndromes Acute Myeloid Leukemia Date: 2016-07-20 Interventions: Drug: H3B-8800 H3B-8800 capsules will be administered at assigned dose regimen (at the maximum tolerated |
Recruiting |
Study Name: Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia Condition: Leukemia, Myelomonocytic, Chronic Date: 2016-06-15 Interventions: Drug: Tipifarnib Oral tablet Other Names: |
Recruiting |
Study Name: An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) Condition: Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic Date: 2015-11-18 Interventions: Drug: Azacitidine Azacitidine |
Recruiting |
Study Name: Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) Condition: Chronic Myelomonocytic Leukemia (CMML) Date: 2015-08-27 Interventions: Drug: lenzilumab Other Names: KB003 Monoclonal Antibody |
Recruiting |
Study Name: SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia) Condition: Myelofibrosis Chronic Myelomonocytic Leukemia Date: 2014-10-10 Interventions: Drug: SL-401 |
Completed |
Study Name: Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Condition: Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic Date: 2014-07-25 Interventions: Drug: Azacitidine Azacitidine |